Q4 2025 Management View Krish Krishnan, CEO, stated Krystal Biotech "made meaningful progress across all geographies" in 2025 ...

Krystal Biotech Inc (NASDAQ:KRYS) on Tuesday delivered fourth-quarter results that came in ahead of Wall Street forecasts, ...

Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo stock exchange next week, the business’ CEO has confirmed. | Japan-based cell therapy company ...

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent ...

A group of European venture capital firms is banding together to try to improve the funding landscape for biotech startups.

KKR, Reddit, SpyGlass Pharma, and Veradermics saw huge insider buying in the past week, a bullish signal for their future ...

Two biotechs take full floors at Waltham’s GENESIS 21 Hickory — about 48K sq ft added to the Route 128 lab campus.

Krystal Biotech (KRYS) stock gains as the company wins FDA RMAT designation for its lung cancer therapy KB707. Read more here ...